What Makes Summit Therapeutics (SMMT) One of the Best Large Caps Under $30

Core Insights - Summit Therapeutics (NASDAQ:SMMT) is identified as one of the 15 large-cap stocks under $30 with significant upside potential [1] - Jefferies downgraded Summit's rating from Buy to Hold and revised the target price from $42 to $15, citing four major catalysts for 2026, each with associated risks [1][2] Company Overview - Summit Therapeutics is a clinical-stage biopharma company focused on developing and commercializing medical oncology therapies, particularly ivonescimab, a bispecific antibody targeting PD-1 and anti-angiogenesis [5] - The company is conducting Phase III clinical trials for the treatment of non-small cell lung cancer [5] Financial Performance - In its fourth-quarter report, Summit Therapeutics posted an adjusted EPS of (14 cents), surpassing the consensus estimate of (1 cent), indicating solid operational performance [3] - The company provided updates on its global Phase III HARMONi-3 clinical trial, showing progress in both squamous and non-squamous cohorts [3] Clinical Trial Updates - Screening for the squamous cohort was completed in the first quarter of 2026, while enrollment for the non-squamous cohort is expected to conclude in the second half of the year [4] - Interim analyses for progression-free survival (PFS) and overall survival (OS) are planned at pre-specified milestones to ensure robust data assessment [4]